Valneva SE
Valneva SE is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA.
It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013.
Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis and Dukoral, a vaccine against cholera
Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa, V710, a therapeutic vaccine against Staphylococcus aureus, and IC41, therapeutic vaccine against hepatitis C
